Loyal / Cellular Longevity

Loyal / Cellular Longevity is a biotechnology startup founded in 2019 in the United States. The company's slogan, "Loyal is developing the first-ever drugs intended to extend the healthspan and lifespan of dogs," encapsulates their mission. As part of Cellular Longevity, they aim to develop drugs explicitly intended to extend healthspan and lifespan, initially in dogs and eventually in humans.

By quantifying and controlling the mechanisms of aging, Loyal aspires to delay the onset and reduce the severity of age-related diseases, ultimately leading to more, healthier years for both species. The company's focus is on longevity and healthspan in dogs, with the objective to offer products that cater to this. Their recent achievement includes a $12.00M Debt Financing investment on 21 March 2024, secured from Bridge Bank.

With their innovative approach and vision, Loyal / Cellular Longevity presents an intriguing opportunity for investors looking to tap into the potential of biotechnology and longevity research. As they venture into uncharted territory with their groundbreaking drugs, the company not only aims for commercial success but also promises to make a significant impact on the well-being and longevity of dogs, and potentially, humans as well.